Lead Product(s) : Theophylline
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Strides Gets USFDA Nod for Theophylline Extended-Release Tablets
Details : Theophylline extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Product Name : Theo-Dur-Generic
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
July 09, 2024
Lead Product(s) : Theophylline
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Kyorin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Kyorin & Cyrano Sign Option Deal for CYR-064 in Post-Viral Smell Loss
Details : Under the agreement, KYORIN obtains an option for the license of the right to develop and commercialize CYR-064. It is being evaluated for the treatment of hyposmia.
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
February 18, 2025
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Kyorin Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cyrano Launches Study on CYR-064 for Hyposmia in Parkinson’s Patients
Details : CYR-064 (theophylline) is an intranasal spray works by inhibiting PDE3/4, currently being evaluated for the treatment of hyposmia in parkinson patients.
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
February 04, 2025
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Theophylline
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Lifesciences gets USFDA nod for asthma treatment drug
Details : Theophylline generic extended-release tablets formulation approved for the use in the treatment of asthma and chronic obstructive pulmonary disease.
Product Name : Theo-Dur-Generic
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
May 22, 2024
Lead Product(s) : Theophylline
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : DeepWork Capital
Deal Size : $9.0 million
Deal Type : Series B Financing
Cyrano Therapeutics Secures $9 Million Series B Financing for CYR-064
Details : Cyrano aims to use proceeds to advance FLAVOR, its Phase 2 trial of CYR-064, an intranasal theophylline spray therapy for patients who lost their sense of smell after viral infections.
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
January 16, 2024
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : DeepWork Capital
Deal Size : $9.0 million
Deal Type : Series B Financing
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYR-064 is a novel, soft-mist nasal-spray product candidate, being developed for the treatment of post-viral smell loss (Hyposmia). It has the potential to become the first pharmaceutical product to restore the senses of smell and taste in patients.
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
December 10, 2023
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : CYR-064 is a soft mist nasal spray therapy to treat patients who have lost their sense of smell following recovery from a viral infection (post-viral hyposmia).
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase II
Sponsor : Remiges Ventures
Deal Size : $12.8 million
Deal Type : Series A Financing
Details : The funds will be used to complete a Phase 2 clinical trial of the company’s lead product, CYR-064, in the U.S. and Europe. As part of the financing, Taka Koda of Remiges Ventures and Gerry Brunk of Lumira Ventures have joined the company’s board of ...
Product Name : CYR-064
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
October 12, 2020
Lead Product(s) : Theophylline
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase II
Sponsor : Remiges Ventures
Deal Size : $12.8 million
Deal Type : Series A Financing
Reset All
Strides Pharma Science: Pioneering IP-driven formulations for niche finished dosage forms.
